Back to INEXION
For Life Sciences
Pharma · Biotech · CROs · AI/ML

The longevity data registry
pharma can't build internally.

Cash-pay longevity is invisible to every incumbent claims-based data platform — IQVIA, Komodo, and Symphony have no pipeline into this setting because the data simply doesn't flow to them. INEXION is building the longitudinal longevity dataset that does not exist anywhere else, structured for HEOR, RWE, clinical trials, and AI/ML training.

Get on the Partner List See Use Cases
$2.7B
RWD licensing market today (→ $7.1B by 2033) — zero longevity coverage in incumbents
4
Buyer segments served — Pharma HEOR, RWE, Trial Sites, AI/ML
50K+
Patient-years targeted by 2027 across the partner network
The Data Gap

The most valuable cohort in healthcare
is invisible to every system built to study it.

Longevity care is delivered through thousands of independent cash-pay practices — outside hospital systems, outside insurance networks. This patient population generates zero claims data. Every legacy health-data platform is claims-first by architecture and structurally cannot reach this cohort.

The structural problem
Claims-based platforms have no pipeline into cash-pay longevity.

IQVIA, Komodo, and Symphony aggregate from insurance claims and hospital EHRs. Cash-pay longevity practices generate neither. The data does not exist in any licensable form — and aggregating it after the fact produces noise, not signal. Schema enforcement at the integration layer is the only way to capture this cohort with research-grade quality.

Building a longitudinal longevity dataset requires either (a) buying every clinic, which is capital-prohibitive and unnecessary, or (b) building the schema and the partnership network from the ground up. INEXION is doing (b).

Why this matters now
Pharma is funding longevity faster than the data is being captured.

Longevity biotech funding surged to $554M in Q4 2025 — a 900%+ increase over Q3. Eli Lilly, Novo Nordisk, and Pfizer all have longevity-adjacent programs (GLP-1s, senolytics, NAD+ pathway modulators) in active development. None of them can model real-world performance, biomarker trajectories, or treatment response patterns in the longevity cohort because the data does not exist.

Nature Aging (DOI: 10.1038/s41514-025-00313-1) recently published a formal biomarker standardization framework calling for pre-competitive shared data tools across multi-site research. INEXION is the physician-embedded delivery layer this framework requires.

What We're Building

A multi-source longitudinal
longevity registry.

INEXION integrates three data layers under a unified schema. The registry is structured for research, benchmarking, and licensing — built by a CTO who architected the same kind of infrastructure for 50M patients at Verana Health.

Public-Data Spine
NHANES, BRFSS, and HRS deployed today. MIDAS arriving within weeks. All of Us in pipeline. The population-level baseline against which partner-contributed cohorts are benchmarked.
Private Partner Contributions
Telehealth platforms, longevity clinics, and EHR partners contributing de-identified patient outcomes under standard Data Use Agreements. The cash-pay longevity cohort captured in research-grade form for the first time.
Medical Society Partnerships
A4M (American Academy of Anti-Aging Medicine) and Longevity Docs in active partnership discussions. Society partnerships bring physician network breadth — practitioners contribute to the registry under a unified schema.
Schema Enforcement at Integration Layer
Standard data model applied at the point of contribution — not retroactively cleaned. Built and operated by a CTO who architected Verana Health's data lake spanning 50M patients and seven years of longitudinal EMR. HIPAA-compliant, fully de-identified, audited at every layer.
Use Cases

Who buys longevity data.
What problem it solves.

Four buyer segments, each with a distinct use case and pricing range. The registry is built to serve all four.

Pharma HEOR & Clinical Operations
Buyers: HEOR teams and Clinical Operations leadership at Eli Lilly, Novo Nordisk, Pfizer, Amgen — pharmas with active longevity-adjacent programs in GLP-1s, senolytics, and NAD+ pathway modulators.

Problem: Zero structured real-world outcome data for longevity interventions. Cannot model biomarker trajectories or treatment response patterns. The data does not exist in any licensable form.

Engagement: $150K–$400K per study · 12–18× platform multiple at scale.
Real World Evidence — Longevity Biotech
Buyers: R&D leads and CMOs at Insilico Medicine, Life Biosciences, Rubedo Life Sciences. 145+ active anti-aging clinical trials worldwide.

Problem: Designing trials against a therapeutic category with no historical dataset. Every other area has decades of accumulated RWD. Longevity has none. Need comparator arm data, biomarker validation, retrospective outcomes.

Engagement: $75K–$500K per study · sponsor-funded · network-effect compounding.
Distributed Trial Site Network
Buyers: VP-level Clinical Development and Site Strategy leaders at pharma sponsors and CROs (Parexel, Syneos, ICON).

Problem: No established trial site network for longevity medicine. Traditional networks (Advarra, WCG) operate through hospital systems that don't treat longevity patients. INEXION's partner network of cash-pay longevity practices provides enrolled populations and geographic distribution for multi-site protocols.

Engagement: $500K–$1.5M per year · uncontested category · forming through 2027.
AI/ML Training Datasets
Buyers: Data science teams at Tempus, Saama Technologies, and AI/ML firms building predictive models. CRO feasibility analysts at Parexel, Syneos, ICON.

Problem: Multimodal longitudinal longevity data — EHR, wearable, PRO, imaging, genomic — does not exist as a training corpus. Can buy claims data. Cannot buy structured longevity data because nobody has aggregated it.

Engagement: $200K–$500K per year · 90%+ gross margin · highest-margin revenue line.
Where We Are

Available now.
Coming through 2027.

INEXION is in the registry stand-up phase. The data architecture is built; partner integration is underway. Licensing contracts begin executing in 2027. Sophisticated pharma and biotech buyers are typically planning two to three years out — early conversations now align with the timeline of registry maturity.

Available now.
Discovery conversations with HEOR, RWE, Clinical Development, and AI/ML teams. Schema preview and data dictionary review under standard NDA. Joint study design sessions with biotech R&D. Early-access partner program enrollment.
Q1–Q2 2027.
Registry at 25–50K patient-years. First HEOR licensing contracts available. RWE study engagements opening. Six or more partner integrations live including at least one EHR platform.
Q3 2027 onward.
Trial site network forming across the partner clinic footprint. AI/ML training dataset licenses available. Multiple licensing contracts active across the four buyer segments.
2028 and beyond.
Registry at 100K+ patient-years across 50+ partners. Publishable, licensable, foundation for pharma research partnerships at scale. Series A funded; platform multiple re-rating.
Partner Pipeline Status
Building

Healthspan data exchange agreement structured. Public-data spine integrated. Multi-platform partnership pipeline in active discussion. Early partner-list spots available.

The Category

The data-platform comp set.
INEXION is the longevity entry.

Every previous data-platform success was the entity that built the dataset incumbents could not. The comp set has consistently rewarded the builder, not the consumer of the data.

Oncology
Flatiron Health
EHR-derived oncology data →
$1.9B Roche acquisition
Ophthalmology
Verana Health
Specialty registry network →
$287M+ raised
Claims Data
Komodo Health
Claims data analytics →
$3.3B valuation
Longevity
INEXION
Longitudinal longevity registry →
Category does not yet exist
Get Started

Three ways to engage
with the registry.

The fastest path is a 30-minute discovery conversation. We'll understand your use case, share the schema preview, and align on the appropriate engagement structure.

01
Discovery Call
30-minute call with the INEXION team to understand your use case, target buyer segment, and timeline. Schema preview shared under standard NDA.
02
Partner List Enrollment
Early-access program for pharma, biotech, and CRO partners. Quarterly registry updates, schema versioning, partnership integration roadmap, and first-look access on licensing engagements as they activate.
03
Joint Research
For sponsors with a specific therapeutic question, we co-design a study using the registry framework — defining the cohort, biomarkers, comparators, and protocol. Engagement structure is finalized as the registry reaches the relevant scale.
Built By

Operators with the right
healthcare-data DNA.

Nirav Vira
Nirav Vira
Chief Technology Officer
25+ years building healthcare data platforms and AI-powered SaaS products. At Verana Health, built a data lake spanning 50 million patients and seven years of longitudinal EMR data. At WithMe Health as CTO, architected a multi-product ecosystem with three distinct revenue lines. At Change Healthcare, built the "Single Source of Truth" data infrastructure powering enterprise analytics. The same kind of infrastructure work, applied to longevity.
Anant Vinjamoori
Anant Vinjamoori, MD
Chief Medical Officer
MD and MBA from Harvard. Founder of Next Generation Medicine, previously at Virta Health. 10+ peer-reviewed publications and one of longevity medicine's most recognized clinical voices. Anant ensures the registry schema and data definitions reflect actual clinical practice — not theoretical taxonomies — so what we license is research-grade.
Ian Wendt
Ian Wendt
Founder & CEO
Three decades of biopharma commercial leadership. Most recently Chief Commercial Officer at Jaguar Health, with deep expertise in launch strategy, market access, and pharma BD. Ian leads INEXION's commercial strategy and the relationship with pharma, biotech, and CRO partners.
For Life Sciences Partners
Get on the partner list.
Pharma HEOR, biotech R&D, CROs, and AI/ML teams in the registry partner program get early access, schema previews, and first-look on licensing engagements as they activate. The fastest path is a 30-minute discovery conversation.
Email to Engage